Compare New York Times Co (NYT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Recursion Pharmaceuticals Inc — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: New York Times Co is far larger — about 8× Recursion Pharmaceuticals Inc's market cap, and New York Times Co pays a 1.21% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NYT | RXRX | |
|---|---|---|
Market Cap | $12.29B | $1.53B |
Sector | Media | Health |
52-Week High | $85.86 | $6.79 |
52-Week Low | $51.43 | $2.84 |
Enterprise Value | $11.68B | $946.50M |
Dividend Yield | 1.21% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
